Summary

Topical Antibiotics Market – Scope of Report
TMR’s report on the global topical antibiotics market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global topical antibiotics market for the period 2017–2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global topical antibiotics market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the topical antibiotics market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global topical antibiotics market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global topical antibiotics market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global topical antibiotics market.

The report delves into the competitive landscape of the global topical antibiotics market. Key players operating in the global topical antibiotics market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global topical antibiotics market profiled in this report.

Key Questions Answered in Global topical antibiotics Market Report
• What is the sales/revenue generated by topical antibiotics across all regions during the forecast period?
• What are the opportunities in the global topical antibiotics market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2031?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Topical Antibiotics Market – Research Objectives and Research Approach
The comprehensive report on the global topical antibiotics market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global topical antibiotics market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global topical antibiotics market.

ページTOPに戻る

Table of Contents

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Topical Antibiotics Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Topical Antibiotics Market Analysis and Forecast, 2017–2031
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Topical Antibiotics Market Analysis and Forecast, by Drug Class
6.1. Introduction and Definitions
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Drug Class, 2017–2031
6.3.1. Tetracycline
6.3.2. Amino-glycosides
6.3.3. Erythromycin
6.3.4. Clindamycin
6.3.5. Others
6.4. Market Attractiveness, by Drug Class
7. Global Topical Antibiotics Market Analysis and Forecast, by Dosage Form
7.1. Introduction and Definitions
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Dosage Form, 2017–2031
7.3.1. Ointments
7.3.2. Creams
7.3.3. Powders
7.3.4. Gels
7.3.5. Others
7.3.6. 7.4 Market Attractiveness, by Dosage Form
8. Global Topical Antibiotics Market Analysis and Forecast, By Indication
8.1. Introduction and Definitions
8.2. Key Findings/Developments
8.3. Market Value Forecast, By Indication, 2017–2031
8.3.1. Skin Infection
8.3.2. Eye Infection
8.3.3. Bromhidrosis
8.3.4. Others
8.4. Market Attractiveness, By Indication
9. Global Topical Antibiotics Market Analysis and Forecast, by Product Type
9.1. Introduction and Definitions
9.2. Key Findings/Developments
9.3. Market Value Forecast, by Product Type, 2017–2031
9.3.1. Prescription
9.3.2. OTC
9.4. Market Attractiveness, by Product Type
10. Global Topical Antibiotics Market Analysis and Forecast, by Distribution Channel
10.1. Introduction and Definitions
10.2. Key Findings/Developments
10.3. Market Value Forecast, by Distribution Channel, 2017–2031
10.3.1. Hospital Pharmacies
10.3.2. Retail Pharmacies
10.3.3. Others
10.4. Market Attractiveness, by Distribution Channel
11. Global Topical Antibiotics Market Analysis and Forecast, by Region
11.1. Key Findings
11.2. Market Value Forecast, by Region, 2017–2031
11.2.1. North America
11.2.2. Europe
11.2.3. Asia Pacific
11.2.4. Latin America
11.2.5. Middle East & Africa
11.3. Market Attractiveness, by Region
12. North America Topical Antibiotics Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Drug Class, 2017–2031
12.2.1. Tetracycline
12.2.2. Amino-glycosides
12.2.3. Erythromycin
12.2.4. Clindamycin
12.2.5. Others
12.3. Market Attractiveness, by Drug Class
12.4. Market Value Forecast, by Dosage Form, 2017–2031
12.4.1. Ointments
12.4.2. Creams
12.4.3. Powders
12.4.4. Gels
12.4.5. Others
12.5. Market Attractiveness, by Dosage Form
12.6. Market Value Forecast, By Indication, 2017–2031
12.6.1. Skin Infection
12.6.2. Eye Infection
12.6.3. Bromhidrosis
12.6.4. Others
12.7. Market Attractiveness, By Indication
12.8. Market Value Forecast, by Product Type, 2017–2031
12.8.1. Prescription
12.8.2. OTC
12.9. Market Attractiveness, by Product Type
12.10. Market Value Forecast, by Distribution Channel, 2017–2031
12.10.1. Hospital Pharmacies
12.10.2. Retail Pharmacies
12.10.3. Others
12.11. Market Attractiveness, by Distribution Channel
12.12. Market Value Forecast, by Country/Sub-region, 2017–2031
12.12.1. U.S.
12.12.2. Canada
12.13. Market Attractiveness Analysis
12.13.1. By Drug Class
12.13.2. By Dosage Form
12.13.3. By Indication
12.13.4. By Product Type
12.13.5. By Distribution Channel
12.13.6. By Country
13. Europe Topical Antibiotics Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Drug Class, 2017–2031
13.2.1. Tetracycline
13.2.2. Amino-glycosides
13.2.3. Erythromycin
13.2.4. Clindamycin
13.2.5. Others
13.3. Market Attractiveness, by Drug Class
13.4. Market Value Forecast, by Dosage Form, 2017–2031
13.4.1. Ointments
13.4.2. Creams
13.4.3. Powders
13.4.4. Gels
13.4.5. Others
13.5. Market Attractiveness, by Dosage Form
13.6. Market Value Forecast, By Indication, 2017–2031
13.6.1. Skin Infection
13.6.2. Eye Infection
13.6.3. Bromhidrosis
13.6.4. Others
13.7. Market Attractiveness, By Indication
13.8. Market Value Forecast, by Product Type, 2017–2031
13.8.1. Prescription
13.8.2. OTC
13.9. Market Attractiveness, by Product Type
13.10. Market Value Forecast, by Distribution Channel, 2017–2031
13.10.1. Hospital Pharmacies
13.10.2. Retail Pharmacies
13.10.3. Others
13.11. Market Attractiveness, by Distribution Channel
13.12. Market Value Forecast, by Country/Sub-region, 2017–2031
13.12.1. Germany
13.12.2. U.K.
13.12.3. France
13.12.4. Italy
13.12.5. Spain
13.12.6. Rest of Europe
13.13. Market Attractiveness Analysis
13.13.1. By Drug Class
13.13.2. By Dosage Form
13.13.3. By Indication
13.13.4. By Product Type
13.13.5. By Distribution Channel
13.13.6. By Country/Sub-region
14. Asia Pacific Topical Antibiotics Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Drug Class, 2017–2031
14.2.1. Tetracycline
14.2.2. Amino-glycosides
14.2.3. Erythromycin
14.2.4. Clindamycin
14.2.5. Others
14.3. Market Attractiveness, by Drug Class
14.4. Market Value Forecast, by Dosage Form, 2017–2031
14.4.1. Ointments
14.4.2. Creams
14.4.3. Powders
14.4.4. Gels
14.4.5. Others
14.5. Market Attractiveness, by Dosage Form
14.6. Market Value Forecast, By Indication, 2017–2031
14.6.1. Skin Infection
14.6.2. Eye Infection
14.6.3. Bromhidrosis
14.6.4. Others
14.7. Market Attractiveness, By Indication
14.8. Market Value Forecast, by Product Type, 2017–2031
14.8.1. Prescription
14.8.2. OTC
14.9. Market Attractiveness, by Product Type
14.10. Market Value Forecast, by Distribution Channel, 2017–2031
14.10.1. Hospital Pharmacies
14.10.2. Retail Pharmacies
14.10.3. Others
14.11. Market Attractiveness, by Distribution Channel
14.12. Market Value Forecast, by Country/Sub-region, 2017–2031
14.12.1. China
14.12.2. Japan
14.12.3. India
14.12.4. Australia & New Zealand
14.12.5. Rest of Asia Pacific
14.13. Market Attractiveness Analysis
14.13.1. By Drug Class
14.13.2. By Dosage Form
14.13.3. By Indication
14.13.4. By Product Type
14.13.5. By Distribution Channel
14.13.6. By Country/Sub-region
15. Latin America Topical Antibiotics Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Drug Class, 2017–2031
15.2.1. Tetracycline
15.2.2. Amino-glycosides
15.2.3. Erythromycin
15.2.4. Clindamycin
15.2.5. Others
15.3. Market Attractiveness, by Drug Class
15.4. Market Value Forecast, by Dosage Form, 2017–2031
15.4.1. Ointments
15.4.2. Creams
15.4.3. Powders
15.4.4. Gels
15.4.5. Others
15.5. Market Attractiveness, by Dosage Form
15.6. Market Value Forecast, By Indication, 2017–2031
15.6.1. Skin Infection
15.6.2. Eye Infection
15.6.3. Bromhidrosis
15.6.4. Others
15.7. Market Attractiveness, By Indication
15.8. Market Value Forecast, by Product Type, 2017–2031
15.8.1. Prescription
15.8.2. OTC
15.9. Market Attractiveness, by Product Type
15.10. Market Value Forecast, by Distribution Channel, 2017–2031
15.10.1. Hospital Pharmacies
15.10.2. Retail Pharmacies
15.10.3. Others
15.11. Market Attractiveness, by Distribution Channel
15.12. Market Value Forecast, by Country/Sub-region, 2017–2031
15.12.1. Brazil
15.12.2. Mexico
15.12.3. Rest of Latin America
15.13. Market Attractiveness Analysis
15.13.1. By Drug Class
15.13.2. By Dosage Form
15.13.3. By Indication
15.13.4. By Product Type
15.13.5. By Distribution Channel
15.13.6. By Country/Sub-region
16. Middle East & Africa Topical Antibiotics Market Analysis and Forecast
16.1. Introduction
16.1.1. Key Findings
16.2. Market Value Forecast, by Drug Class, 2017–2031
16.2.1. Tetracycline
16.2.2. Amino-glycosides
16.2.3. Erythromycin
16.2.4. Clindamycin
16.2.5. Others
16.3. Market Attractiveness, by Drug Class
16.4. Market Value Forecast, by Dosage Form, 2017–2031
16.4.1. Ointments
16.4.2. Creams
16.4.3. Powders
16.4.4. Gels
16.4.5. Others
16.5. Market Attractiveness, by Dosage Form
16.6. Market Value Forecast, By Indication, 2017–2031
16.6.1. Skin Infection
16.6.2. Eye Infection
16.6.3. Bromhidrosis
16.6.4. Others
16.7. Market Attractiveness, By Indication
16.8. Market Value Forecast, by Product Type, 2017–2031
16.8.1. Prescription
16.8.2. OTC
16.9. Market Attractiveness, by Product Type
16.10. Market Value Forecast, by Distribution Channel, 2017–2031
16.10.1. Hospital Pharmacies
16.10.2. Retail Pharmacies
16.10.3. Others
16.11. Market Attractiveness, by Distribution Channel
16.12. Market Value Forecast, by Country/Sub-region, 2017–2031
16.12.1. GCC Countries
16.12.2. South Africa
16.12.3. Rest of Middle East & Africa
16.13. Market Attractiveness Analysis
16.13.1. By Drug Class
16.13.2. By Dosage Form
16.13.3. By Indication
16.13.4. By Product Type
16.13.5. By Distribution Channel
16.13.6. By Country/Sub-region
17. Competition Landscape
17.1. Market Player – Competition Matrix (By Tier and Size of Companies)
17.2. Market Share Analysis, by Company (2022)
17.3. Company Profiles
17.3.1. Novartis AG
17.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.1.2. Product Portfolio
17.3.1.3. Financial Overview
17.3.1.4. SWOT Analysis
17.3.1.5. Strategic Overview
17.3.2. GlaxoSmithKline plc
17.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.2.2. Product Portfolio
17.3.2.3. Financial Overview
17.3.2.4. SWOT Analysis
17.3.2.5. Strategic Overview
17.3.3. Perrigo Company plc
17.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.3.2. Product Portfolio
17.3.3.3. Financial Overview
17.3.3.4. SWOT Analysis
17.3.3.5. Strategic Overview
17.3.4. Pfizer, Inc.
17.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.4.2. Product Portfolio
17.3.4.3. Financial Overview
17.3.4.4. SWOT Analysis
17.3.4.5. Strategic Overview
17.3.5. Almirall, SA
17.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.5.2. Product Portfolio
17.3.5.3. Financial Overview
17.3.5.4. SWOT Analysis
17.3.5.5. Strategic Overview
17.3.6. Bausch Health Companies, Inc. (Valeant Pharmaceuticals International, Inc.)
17.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.6.2. Product Portfolio
17.3.6.3. Financial Overview
17.3.6.4. SWOT Analysis
17.3.6.5. Strategic Overview
17.3.7. Medimetriks Pharmaceuticals, Inc.
17.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.7.2. Product Portfolio
17.3.7.3. Financial Overview
17.3.7.4. SWOT Analysis
17.3.7.5. Strategic Overview
17.3.8. Taro Pharmaceutical Industries Ltd.
17.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.8.2. Product Portfolio
17.3.8.3. Financial Overview
17.3.8.4. SWOT Analysis
17.3.8.5. Strategic Overview
17.3.9. Mayne Pharma Group Ltd.
17.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.9.2. Product Portfolio
17.3.9.3. Financial Overview
17.3.9.4. SWOT Analysis
17.3.9.5. Strategic Overview